Equities research analysts predict that Kalvista Pharmaceuticals Inc (NASDAQ:KALV) will report $3.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Kalvista Pharmaceuticals’ earnings. The highest sales estimate is $3.70 million and the lowest is $3.00 million. Kalvista Pharmaceuticals posted sales of $5.59 million during the same quarter last year, which suggests a negative year-over-year growth rate of 41%. The firm is expected to announce its next earnings report on Friday, December 13th.

On average, analysts expect that Kalvista Pharmaceuticals will report full year sales of $18.55 million for the current fiscal year, with estimates ranging from $10.00 million to $36.58 million. For the next year, analysts forecast that the business will report sales of $6.07 million, with estimates ranging from $2.13 million to $10.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, September 9th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.20. Kalvista Pharmaceuticals had a negative net margin of 144.64% and a negative return on equity of 22.25%. The firm had revenue of $3.37 million for the quarter, compared to analysts’ expectations of $3.24 million.

Several equities research analysts have commented on KALV shares. BidaskClub cut shares of Kalvista Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. Leerink Swann started coverage on shares of Kalvista Pharmaceuticals in a research report on Monday, July 29th. They issued an “outperform” rating and a $31.00 price target on the stock. Svb Leerink started coverage on shares of Kalvista Pharmaceuticals in a research report on Monday, July 29th. They issued an “outperform” rating and a $31.00 price target on the stock. Zacks Investment Research cut shares of Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Wednesday, July 17th. Finally, Roth Capital set a $30.00 price target on shares of Kalvista Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 6th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $29.86.

In related news, Director Albert Cha acquired 61,280 shares of the business’s stock in a transaction on Friday, July 19th. The shares were purchased at an average price of $17.79 per share, for a total transaction of $1,090,171.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas Andrew Crockett sold 10,000 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.04, for a total value of $170,400.00. Following the sale, the chief executive officer now owns 248,510 shares in the company, valued at approximately $4,234,610.40. The disclosure for this sale can be found here. In the last 90 days, insiders have acquired 145,427 shares of company stock worth $2,515,550. Corporate insiders own 21.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in KALV. Cubist Systematic Strategies LLC purchased a new position in Kalvista Pharmaceuticals during the 2nd quarter valued at about $42,000. Strs Ohio purchased a new position in Kalvista Pharmaceuticals during the 2nd quarter valued at about $68,000. Bank of Montreal Can grew its stake in Kalvista Pharmaceuticals by 28.5% during the 1st quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock valued at $166,000 after acquiring an additional 1,292 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in Kalvista Pharmaceuticals during the 1st quarter valued at about $175,000. Finally, Virtus ETF Advisers LLC purchased a new position in Kalvista Pharmaceuticals during the 2nd quarter valued at about $297,000. 82.98% of the stock is currently owned by institutional investors.

Kalvista Pharmaceuticals stock traded down $0.40 during midday trading on Monday, hitting $15.60. The company’s stock had a trading volume of 68,595 shares, compared to its average volume of 138,120. The stock’s 50-day moving average price is $16.01 and its 200-day moving average price is $21.37. Kalvista Pharmaceuticals has a 12 month low of $14.50 and a 12 month high of $34.92. The company has a market capitalization of $292.78 million, a PE ratio of -11.30 and a beta of 2.11.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Story: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.